Intercontinental Wealth Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$360K Sell
2,564
-60
-2% -$8.27K 0.09% 233
2023
Q1
$371K Sell
2,624
-804
-23% -$115K 0.09% 233
2022
Q4
$536K Sell
3,428
-3
-0.1% -$431 0.16% 152
2022
Q3
$421K Sell
3,431
-12
-0.3% -$1.58K 0.13% 180
2022
Q2
$458K Sell
3,443
-13
-0.4% -$1.77K 0.12% 175
2022
Q1
$473K Sell
3,456
-8
-0.2% -$1.11K 0.11% 185
2021
Q4
$599K Sell
3,464
-439
-11% -$66.8K 0.13% 163
2021
Q3
$567K Sell
3,903
-62
-2% -$9.07K 0.13% 150
2021
Q2
$523K Buy
3,965
+202
+5% +$26.4K 0.1% 172
2021
Q1
$483K Buy
3,763
+94
+3% +$11.6K 0.11% 162
2020
Q4
$437K Sell
3,669
-3,872
-51% -$472K 0.11% 157
2020
Q3
$863K Sell
7,541
-462
-6% -$54.6K 0.25% 78
2020
Q2
$912K Buy
8,003
+2,107
+36% +$223K 0.3% 72
2020
Q1
$473K Buy
+5,896
New +$610K 0.25% 91

Other funds holding DGX

Intercontinental Wealth Advisors's DGX Position: Q2 2023 in Review

Intercontinental Wealth Advisors reduced its Quest Diagnostics (DGX) stake by 2.3% in Q2 2023, selling an estimated $8.27K and leaving 2,564 shares worth $360K. The position accounts for 0.09% of the portfolio, ranked #233.

Intercontinental Wealth Advisors first reported a position in DGX in Q1 2020 and has held it in 14 quarters since. The position peaked at $912K in Q2 2020. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

  • Intercontinental Wealth Advisors held 2,564 shares of Quest Diagnostics worth $360K as of Q2 2023.
  • Intercontinental Wealth Advisors sold 60 Quest Diagnostics shares in Q2 2023, an estimated $8.27K.
  • Quest Diagnostics made up 0.09% of Intercontinental Wealth Advisors's portfolio in Q2 2023, its #233 holding.
  • Intercontinental Wealth Advisors first reported a position in Quest Diagnostics in Q1 2020 and has held it in 14 quarters since.
  • Intercontinental Wealth Advisors's Quest Diagnostics position peaked at $912K in Q2 2020.
  • 818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Intercontinental Wealth Advisors's 13F filing for Q2 2023, filed 21 Jul 2023.